Navigation Links
U.S. and European Rheumatologists Agree That a Therapy's Induction of Remission is One of the Attributes That Most Influences Their Prescribing Decisions in Rheumatoid Arthritis
Date:6/19/2013

BURLINGTON, Mass., June 19, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of rheumatoid arthritis, the majority of surveyed U.S. and European rheumatologists cite a therapy's induction of remission as one of the attributes that most influences their prescribing decisions. Over 60 percent and 70 percent of U.S. and European rheumatologists, respectively, rank the percentage of patients achieving remission at six months as one of the top three most persuasive end points when prescribing a new drug for rheumatoid arthritis.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The DecisionBase rheumatoid arthritis report entitled In a Market Filled with Efficacious Drugs, Which Efficacy and Safety Achievements Have the Greatest Influence with Physicians and Payers? finds that surveyed rheumatologists also indicate there is a moderate unmet need for therapies with a greater ability to induce remission. Therapies with a greater ability to induce remission at six months have a meaningful opportunity for differentiation.

The report also finds that, according to interviewed thought leaders and clinical data, tocilizumab (Roche/Chugai's Actemra/RoActemra) has a minor advantage over AbbVie/Eisai's Humira for its ability to effect remission at six months, whereas Pfizer/Takeda's Xeljanz is at a disadvantage to Humira on this end point. 

"However, in spite of thought-leader opinion and clinical trial data support for IV tocilizumab's excellent efficacy, the drug is predominantly used as a later-line biologic because of payer restrictions, concerns about monitoring and managing its side effects, its more-limited postmarketing experience and its need for IV infusion," said Decision Resources Senior Director Madhuri Borde, Ph.D.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or
registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
2. CTI Announces Data Presentations at the 18th Congress of the European Hematology Association
3. Hospira Data on European Biosimilar Epoetin, Retacrit, Affirm Treatment Response, Tolerability in Management of Anemia Secondary to Chemotherapy
4. Oramed Selected to Present at the 81st European Atherosclerosis Society Congress in Lyon, France, June 2-5, 2013
5. Cardica Completes Enrollment In European Clinical Trial For Surgical Cutting And Stapling Device
6. Life Care Medical Devices Ltd Announces Addition Of Dublin, Ireland Based European Subsidiary
7. The European Alcohol Addiction Market is Poised For a Treatment Paradigm Shift With the Launch of BioTie/Lundbecks Selincro
8. Demand for Hybrid Solutions to Spur European Interventional Radiology and Cardiology Markets, finds Frost & Sullivan
9. Janssen and Johnson & Johnson to Provide Webcast Presentation of Simeprevir Phase 3 Clinical Data Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
10. Combination Drugs are the Future of the European Hepatitis B and C Therapeutics Markets, Says Frost & Sullivan
11. Omeros Ophthalmology Product OMS302 Granted Eligibility for European Centralized Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2019)... ... May 22, 2019 , ... A leading global health expert urged new ... that celebrates past health care successes and builds on them to make better lives ... professor of global health at the University of Washington and Institute Director of the ...
(Date:5/22/2019)... ... May 22, 2019 , ... CBDNhance, a ... Ultra-Relief and Ultra-Relax, that are designed to increase the benefits of CBD, especially ... but instead contain terpenes and other natural ingredients that have been shown to ...
(Date:5/22/2019)... ... ... Americans can save more money on generic drugs at U.S. pharmacies than ... the top-selling generic drugs. Eighty-eight percent of the top prescribed generics were cheaper in ... at Canadian and other international online pharmacies than in the U.S. , In ...
Breaking Medicine Technology:
(Date:5/23/2019)... ... May 23, 2019 , ... Neurohacker Collective , ... with Emerson Ecologics. Qualia Mind, Qualia Focus, and Qualia Mind Caffeine Free are ... Emerson’s extensive nearly 40 year history of providing the broadest selection of wellness ...
(Date:5/22/2019)... ... May 22, 2019 , ... Impact Advisors , a leading provider of ... it has been named to Becker’s Hospital Review’s 150+ Top Places to Work in ... , “It is a great honor to be named to Becker’s ...
(Date:5/22/2019)... ... May 22, 2019 , ... With record-breaking starting positions, three drivers from Ed Carpenter Racing ... have qualified their Chevrolets for the team’s entry in the 103rd running of the ... qualifying run, Pigot was sitting in pole position in his No. 21 Autogeek ...
(Date:5/22/2019)... ... May 22, 2019 , ... In ... implementation of a common management structure that aligns both the east and west ... Calif. has become Avante Ultrasound’s west coast operations center, and Global Medical Imaging ...
(Date:5/22/2019)... ... May 22, 2019 , ... Today, ... reducing rates of cervical cancer among transmasculine patients who were assigned a female ... spectrum of masculinity. Although over 90 percent of such patients retain female reproductive ...
Breaking Medicine News(10 mins):